Boston University Libraries OpenBU
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    •   OpenBU
    • School of Medicine
    • Clinical Science
    • Department of Medicine
    • MED: Medicine Papers
    • View Item
    •   OpenBU
    • School of Medicine
    • Clinical Science
    • Department of Medicine
    • MED: Medicine Papers
    • View Item

    Nonsteroidal Anti-Inflammatory Drug Use and Alzheimer's Disease Risk: The MIRAGE Study

    Thumbnail
    License
    Copyright 2005 Yip et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Date Issued
    2005-1-12
    Publisher Version
    10.1186/1471-2318-5-2
    Author(s)
    Yip, Agustín G.
    Green, Robert C.
    Huyck, Matthew
    Cupples, L. Adrienne
    Farrer, Lindsay A.
    Share to FacebookShare to TwitterShare by Email
    Export Citation
    Download to BibTex
    Download to EndNote/RefMan (RIS)
    Metadata
    Show full item record
    Permanent Link
    https://hdl.handle.net/2144/2489
    Citation (published version)
    Yip, Agustín G, Robert C Green, Matthew Huyck, L Adrienne Cupples, Lindsay A Farrer. "Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study." BMC Geriatrics5:2. (2005)
    Abstract
    BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAID) use may protect against Alzheimer's disease (AD) risk. We sought examine the association between NSAID use and risk of AD, and potential effect modification by APOE-ε4 carrier status and ethnicity. METHODS: The MIRAGE Study is a multi-center family study of genetic and environmental risk factors for AD. Subjects comprised 691 AD patients (probands) and 973 family members enrolled at 15 research centers between 1996 and 2002. The primary independent and dependent variables were prior NSAID use and AD case status, respectively. We stratified the dataset in order to evaluate whether the association between NSAID use and AD was similar in APOE-ε4 carriers and non-carriers. Ethnicity was similarly examined as an effect modifier. RESULTS: NSAID use was less frequent in cases compared to controls in the overall sample (adjusted OR = 0.64; 95% CI = 0.38–1.05). The benefit of NSAID use appeared more pronounced among APOE-ε4 carriers (adjusted OR = 0.49; 95% CI = 0.24–0.98) compared to non-carriers, although this association was not statistically significant. The pattern of association was similar in Caucasian and African Americans. CONCLUSIONS: NSAID use is inversely associated with AD and may be modified by APOE genotype. Prospective studies and clinical trials of sufficient power to detect effect modification by APOE-ε4 carrier status are needed.
    Rights
    Copyright 2005 Yip et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Collections
    • MED: Medicine Papers [241]
    • SPH Biostatistics Papers [124]
    • SPH Epidemiology Papers [104]
    • MED: Genetics & Genomics Papers [17]
    • MED: Neurology Scholarly Works [67]


    Boston University
    Contact Us | Send Feedback | Help
     

     

    Browse

    All of OpenBUCommunities & CollectionsIssue DateAuthorsTitlesSubjectsThis CollectionIssue DateAuthorsTitlesSubjects

    Deposit Materials

    LoginNon-BU Registration

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Boston University
    Contact Us | Send Feedback | Help